






**Supplementary Figure S1. Individual tumor volume plot of the CMT167 model.**

Individual tumor volumes related to Fig. 1D and 1E were plotted in Supplementary Fig. 1A and 1B, respectively.




**Supplementary Figure S2. Correlation between MYC mRNA comparative expression and IC50 value to TAK-981.**


TAK-981 sensitive cells and resistant cells were represented by blue dots and red dots, respectively. IC<sub>50</sub> values of TAK-981 resistant cells were provisionally presented as 10 μM.  $r$ , correlation coefficient;  $R^2$ , square of  $r$  (Pearson correlation coefficient).



**Supplementary Figure S3. MYC protein expression levels by immunoblot of representative TAK-981 sensitive cells (blue) and resistant cells (red).** NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma; CRC, colorectal carcinoma.




**Supplementary Figure S4. Change of SUMOylation inhibition sensitivity by MYC overexpression in TAK-981-resistant cells.** GFP, Green Fluorescent Protein; MYC-OE, MYC-overexpression.



**Supplementary Figure S5. SUMOylation inhibition of short-period in HCT 116 cells.**

HCT 116 cells were treated with DMSO or 1  $\mu$ M TAK-981 for 30 minutes. Samples were analyzed as shown in Figure 3E. IP, immunoprecipitation; WCE, whole cell extract.



**Supplementary Figure S6. MYC expression in AKTP cells.**  
Immunoblot of indicated cells.